CHR
Cheer Holding, Inc.
There isn't enough reported data to score CHR yet.
META
Meta Platforms, Inc.
META's fundamentals are mixed, but it looks cheap: trading at 21x earnings, below its usual 27x. Analysts expect earnings growth, though they disagree widely on how much.
CHR Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Stable | |
| Healthy |
CHR's profitability and balance sheet are currently healthy, and its cash flow is stable, but its revenue is under pressure.
META Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
META's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CHR PE Valuation
CHR has no meaningful PE right now: it lost money over the past year.
META PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $624 | — |
| Cheap | 21x | $613 | -1.7% |
| Current | 21x | $624 | — |
| Fair | 27x | $803 | +29% |
| Expensive | 32x | $934 | +50% |
Historical ranges are pointers, not guarantees.
META's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
CHR Forward outlook
There aren't enough analyst estimates for CHR to show an outlook.
META Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for META, but weaker profitability. However, they disagree widely on these estimates.
CHR Earnings Per Share
CHR and META do not have enough comparable growth data to identify a winner.
META Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.16 | +9.7% |
| Q3 2026 | $29.32 | +30% |
| Q2 2026 | $26.54 | -3.7% |
| Q1 2026 | $27.50 | +7.5% |
| Q4 2025 | $23.49 | -1.6% |
| Q3 2025 | $22.58 | +6.5% |
| Q2 2025 | $27.56 | +41% |
| Q1 2025 | $25.58 | +47% |
| Q4 2024 | $23.86 | +60% |
META earned $29.32 per share over the past year, up 30% from the year before.
CHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $30.3M | -15% |
| Q1 2026 | $30.3M | -15% |
| Q4 2025 | $38.9M | +2.2% |
| Q3 2025 | $38.9M | +2.2% |
| Q2 2025 | $35.5M | -50% |
| Q4 2024 | $38.1M | -55% |
| Q2 2024 | $71.1M | +5.4% |
| Q4 2023 | $84.9M | -2.6% |
CHR's revenue has slid since its 2022 peak: $30M last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 17% | +5.6 points |
| Q1 2026 | 17% | +5.6 points |
| Q4 2025 | 23% | +4.8 points |
| Q3 2025 | 23% | +4.8 points |
| Q2 2025 | 12% | -4.6 points |
| Q1 2025 | 12% | N/A |
| Q4 2024 | 18% | -5.9 points |
| Q3 2024 | 18% | N/A |
CHR's operating margin was 17% last quarter, up 5.6 points from the same quarter a year ago.
META Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.6B | +26% |
| Q2 2026 | $60.8B | +28% |
| Q1 2026 | $56.3B | +33% |
| Q4 2025 | $59.9B | +24% |
| Q3 2025 | $51.2B | +26% |
| Q2 2025 | $47.5B | +22% |
| Q1 2025 | $42.3B | +16% |
| Q4 2024 | $48.4B | +21% |
META has the edge over CHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -20 points |
| Q2 2026 | 31% | -12 points |
| Q1 2026 | 41% | -0.9 points |
| Q4 2025 | 41% | -7 points |
| Q3 2025 | 40% | -2.7 points |
| Q2 2025 | 43% | +5 points |
| Q1 2025 | 41% | +3.6 points |
| Q4 2024 | 48% | +7.4 points |
META has the edge over CHR on profitability, with a higher operating margin.
CHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$15.1M | -871% |
| Q1 2026 | $17.9M | +815% |
| Q4 2025 | $7M | -53% |
| Q3 2025 | $7M | -53% |
| Q2 2025 | $2M | +$8.7M |
| Q1 2025 | $2M | +$5.3M |
| Q4 2024 | $14.8M | -1.3% |
| Q3 2024 | $14.8M | +97% |
CHR has the edge over META on cash flow, with more consistent year-over-year improvement.
META Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -110% |
| Q2 2026 | $1.7B | -81% |
| Q1 2026 | $13.2B | +19% |
| Q4 2025 | $14.8B | +9.3% |
| Q3 2025 | $11.2B | -32% |
| Q2 2025 | $9B | -19% |
| Q1 2025 | $11.1B | -14% |
| Q4 2024 | $13.6B | +16% |
META usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $28.6B over the past year.
CHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -62% | -124K shares |
| 3 years | +1564% | +72.6K shares |
CHR has the edge over META on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
META Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +7M shares |
| 1 year | 0% | +1M shares |
| 3 years | -2.6% | -68M shares |
| 5 years | -10% | -286M shares |
| Available history | -11% | -303M shares |
META has 2.6B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $3.3B |
| Q2 2025 | $10.2B |
| Q1 2025 | $12.8B |
| Q4 2024 | — |
META hasn't bought back shares in the past year.
CHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -4.8x | Net Cash |
| Q1 2026 | -5.0x | Net Cash |
| Q4 2025 | -6.7x | Net Cash |
| Q3 2025 | -7.6x | Net Cash |
| Q2 2025 | -7.5x | Net Cash |
| Q1 2025 | -5.7x | Net Cash |
CHR has the edge over META on leverage, with a lower net debt burden relative to earnings.
META Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.0x | Very low |
| Q4 2024 | -0.2x | Net Cash |
META's net debt is less than a year of its operating earnings (EBITDA).
CHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.6 | Oversold |
| Stochastic | 15.4 | Oversold |
CHR's weekly RSI is 26 (oversold) and its Stochastic is 15 (oversold).
META Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 33.7 | Neutral |
META's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
CHR PE vs Communication Services Sector
CHR has no meaningful PE right now: it lost money over the past year.
META PE vs Communication Services Sector
| Metric | META | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 16x | 29% above |
| PE % | 18 | 26 | 8 pts below |
META is trading at 21x earnings, a 29% premium to the Communication Services sector's median of 16x.
CHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.43 | 7.7% below |
| 20 week MA | $1.67 | 21% below |
| 50 week MA | $2.59 | 49% below |
| 100 week MA | $103.9 | 99% below |
| 200 week MA | $363.1 | 100% below |
CHR is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
META Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $674.9 | 7.6% below |
| 20 week MA | $634.5 | 1.7% below |
| 50 week MA | $630.8 | 1.1% below |
| 100 week MA | $647.8 | 3.7% below |
| 200 week MA | $517.5 | 21% above |
META has the edge over CHR on trend strength, trading above more of its moving averages.
CHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15,450.0 | $3,945.0 | -74% |
| 2021 | $3,945.0 | $1,935.0 | -51% |
| 2022 | $1,935.0 | $2,220.0 | +15% |
| 2023 | $2,220.0 | $471.0 | -79% |
| 2024 | $471.0 | $387.0 | -18% |
| 2025 | $387.0 | $4.38 | -99% |
| 2026 YTD | $4.38 | $1.32 | -70% |
CHR has finished three years in a row lower, and it's down 70% so far in 2026.
META Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $208.1 | $267.4 | +28% |
| 2021 | $267.4 | $335.2 | +25% |
| 2022 | $335.2 | $118.0 | -65% |
| 2023 | $118.0 | $354.0 | +200% |
| 2024 | $354.0 | $599.8 | +69% |
| 2025 | $599.8 | $663.3 | +11% |
| 2026 YTD | $663.3 | $623.6 | -6% |
META has the edge over CHR on returns for 2026, with the stronger performance.